
An FDA task force has been formed to examine transparency at the Food and Drug Administration (FDA). “President Obama has pledged to strengthen our democracy by creating an unprecedented level of openness and public participation in government, and the FDA looks forward to participating in this process,” said FDA Commissioner Margaret A. Hamburg, M.D. “I have asked the Transparency Task Force to deliver recommendations to me for ways to make more information available and foster better understanding of decision-making.”
One public meeting has been held, and a request for public comments has been posted. C3 provided comments urging FDA to review transparency requirements to ensure that the public is given accurate information both pre- and post-approval. Read the rest of this entry »

